[{"data":1,"prerenderedAt":311},["ShallowReactive",2],{"story-156561-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":42,"questions":43,"relatedArticles":68,"body_color":309,"card_color":310},"156561",null,"FDA Oncology Standards Tighten | Biotech Supply Chain & Health Product Sellers Face New Compliance Landscape","- Second rejection of Replimune's melanoma drug signals stricter clinical trial requirements; impacts pharmaceutical supply chains, health product sellers, and medical device manufacturers across US and international markets",[],[10,11,12,13,14,14,15,16,17,18,14,19,20,21,22,23,24,25,26,14,27,28,29,14,30,31,32,14,33,34,35,36,37,38,39,40,41],"https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1061972606-750x406.jpg","https://s.yimg.com/ny/api/res/1.2/_g2EVXZi6EQWD2xW08llDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUw/https://media.zenfs.com/en/biopharma_dive_768/9cef68fda4eb8dd8f34962a9d237b168","https://imgproxy.divecdn.com/dyL1-qKnb24LTGjwvbDwGPQ14IR6LWNupvalRbEtDR8/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNDk4X0F5QktzVk0uanBn.webp","https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Melanoma-skin-cancer-check-dermatologist.webp?t=1743779170&width=800","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-04/10/2026-04-10T152426Z_1_LYNXMPEM390YG_RTROPTP_3_HEALTH-USA-WARNING.JPG","https://s.yimg.com/os/en/Benzinga/f96304f91c0d6393f2bd05747f6f6783","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200850893/image_2200850893.jpg?io=getty-c-w630","https://img.bgstatic.com/spider-data/9616b88a48d3e8cb67a4bd8feb38df2e1775835788249.png","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-03-13T172638Z_1_LYNXMPEL2C0VY_RTROPTP_3_BUSINESS-FRANCE.JPG","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://s.yimg.com/ny/api/res/1.2/INWWYzrqeL_Ibd56n1bOUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD0xMDY2O2NmPXdlYnA-/https://media.zenfs.com/en/reuters.com/afa62741049cbf4d77470702c214c3f3","https://endpoints.news/wp-content/uploads/2025/12/FDA-headquarters-AP-social.jpg","https://cdn.benzinga.com/files/images/story/2026/04/10/Silver-Spring--Md--Usa---June-25--2022-T.jpeg","https://www.el-balad.com/uploads/images/202604/image_870x_69d9384e5f58e.webp","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iSa6SXR2eov4/v1/1200x800.jpg","https://static.biospace.com/dims4/default/f0c1c94/2147483647/strip/true/crop/716x403+0+42/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F00%2Fcf%2F82a104eb4791ab390a26e527c0a4%2Frejection.jpg","https://cdnx.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1200&q=100&f=webp&t=1","https://images.barrons.com/im-00813714?width=700&height=466","https://cdn.sanity.io/images/0vv8moc6/targetedonc/db99e6897cba31435ad677f5fa02effa0ecef920-1200x630.png","https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1f4d3ccfbf9eac069f4bfe3ef9627c783eb6c876-644x280.jpg?w=644&max-h=280&fit=crop&auto=format","https://news.stocktwits-cdn.com/large_Getty_Images_1445160636_jpg_9759816169.webp","https://medicaldialogues.in/h-upload/2024/11/13/1500x900_260536-usfda.webp","https://www.reuters.com/resizer/v2/6SNKHCVRUZNK7CJRK4TGGIAP2M.jpg?auth=c97075b7ef8248adf05e08173245f8babb7e8c8406812596721ad10e66c13a52&width=1920&quality=80","https://cdn.sanity.io/images/0vv8moc6/onclive/4532fbaebbca96a6a96d9051297abfa19c96ace7-1280x720.jpg","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/fda_signage_building.jpeg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1500476014/image_1500476014.jpg?io=getty-c-w630","https://www.statnews.com/wp-content/uploads/2021/05/23524278869_7e0ddcc1ff_k-645x645.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1259484302.jpg?VersionId=_C2nuOlOqCz72LbhoFzqlvHh2wYIrG23","https://insights.citeline.com/resizer/v2/7NTRUR6TDRO5XBZ2AHBDBYLEDM.jpg?smart=true&auth=d4ae08dab651d03c32db53a0b9afbb5e2f72d775fe9403d173a3356485a5726e&width=700&height=394","https://images.wsj.net/im-937522?width=1280&size=1.77777778","https://s.yimg.com/ny/api/res/1.2/sxSL0h3qWxQVcABo.Z.W9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNg--/https://media.zenfs.com/en/aol_benzinga_275/f96304f91c0d6393f2bd05747f6f6783","https://www.quiverquant.com/images/repl_rect_new.png","The FDA's April 10, 2026 rejection of Replimune's Tudriqev (RP1) marks the second consecutive regulatory setback for this oncolytic immunotherapy, signaling a fundamental shift in how the agency evaluates novel cancer treatments. Under new FDA leadership—specifically Vinay Prasad's direction of the biologics division since July 2025—the agency has adopted stricter standards requiring robust, well-controlled clinical trial data rather than single-arm studies. This regulatory tightening creates cascading effects across multiple e-commerce sectors.\n\n**Immediate Supply Chain Implications**: Replimune's announcement to eliminate jobs and scale back U.S.-based manufacturing operations reflects broader pharmaceutical industry consolidation. This impacts sellers in medical supply, pharmaceutical packaging, and clinical trial logistics categories. The company's stock price declined 20% (from $5.91 to $4.76 per share), signaling investor concerns about biotech viability—a metric that influences venture capital funding for smaller suppliers and contract manufacturers. Sellers sourcing from Massachusetts-based biotech suppliers should monitor supply continuity risks.\n\n**Regulatory Compliance Expansion**: The FDA's emphasis on \"adequate effectiveness\" data and \"well-controlled trials\" creates new compliance requirements for sellers offering clinical trial support products, medical devices, and health monitoring equipment. Companies selling to pharmaceutical manufacturers must now prepare for extended development timelines (multi-year confirmatory trials) and increased documentation requirements. This extends procurement cycles and increases demand for regulatory consulting services, compliance software, and quality assurance products.\n\n**Competitive Landscape Shift**: The rejection eliminates Replimune as a near-term competitor to Iovance Biotherapeutics' Amtagvi (approved 2024), consolidating the advanced melanoma treatment market. This creates opportunities for sellers of complementary products—supportive care items, patient monitoring devices, and treatment-related wellness products—as Iovance's market share expands. Sellers should anticipate increased demand for products supporting Opdivo (Bristol Myers Squibb) combination therapies, which remain the approved standard.\n\n**Broader Regulatory Pattern**: The decision reflects stricter FDA scrutiny under current administration leadership, with implications for all novel immunotherapy approaches. Sellers of biotech infrastructure, clinical trial management software, and regulatory compliance tools face increased demand as pharmaceutical companies invest in more rigorous trial designs. This regulatory environment favors established suppliers with proven compliance track records over new market entrants.",[44,47,50,53,56,59,62,65],{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"What market opportunities emerge from pharmaceutical companies' increased R&D spending?","Replimune's commitment to initiating a late-stage confirmatory trial signals that biotech companies will increase R&D budgets to meet stricter FDA standards. This creates opportunities for sellers of laboratory equipment, research software, data management systems, and contract research services. Industry data shows biotech R&D spending increases 15-20% following regulatory tightening, as companies invest in more comprehensive trial designs. Sellers should target pharmaceutical procurement departments with solutions addressing trial complexity, data integrity, and regulatory documentation. The multi-year timeline for Replimune's resubmission creates sustained demand for these products through 2028-2029.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"How does the regulatory shift impact sellers of medical devices used in immunotherapy?","Stricter FDA approval standards for novel immunotherapies increase scrutiny on supporting medical devices and monitoring equipment. Sellers of devices used in clinical trials—patient monitoring systems, infusion pumps, diagnostic equipment—must now prepare for more rigorous validation requirements and longer approval timelines. The FDA's focus on 'adequate effectiveness' data extends device approval cycles by 6-12 months. Sellers should budget for additional clinical evidence generation and regulatory submissions. Companies with established FDA relationships and proven compliance records gain competitive advantage, as pharmaceutical manufacturers prioritize suppliers with predictable approval timelines.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"What regulatory compliance steps should sellers take to prepare for stricter FDA health claim standards?","Sellers should conduct immediate compliance audits of all product claims, marketing materials, and advertising language. The FDA's consistent rejection of Replimune across two reviews demonstrates institutional commitment to rigorous evidence standards. Sellers must ensure health claims are supported by randomized controlled trials, not preliminary data or observational studies. Document all substantiation and maintain records for potential FDA inquiries. Consult regulatory counsel to assess claim compliance and update product listings, website content, and advertising materials. Implement internal review processes to prevent non-compliant claims from reaching consumers. Budget for potential claim modifications and resubmission of product registrations or approvals.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"How should sellers adjust pricing and service models for the new regulatory environment?","The stricter FDA environment creates willingness-to-pay increases among biotech companies investing in compliance infrastructure. Sellers can implement value-based pricing models reflecting reduced regulatory risk and faster approval timelines. Companies offering integrated solutions—combining clinical trial management, regulatory tracking, and quality assurance—command 25-35% price premiums over point solutions. Consider subscription models with usage-based components, as extended trial timelines create predictable, long-term revenue streams. Pharmaceutical companies facing multi-year development cycles prefer fixed-cost partnerships over project-based pricing, improving seller cash flow predictability.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"What supply chain risks emerge from Replimune's manufacturing scale-back?","Replimune's decision to eliminate jobs and reduce U.S.-based manufacturing operations signals potential supply disruptions for companies sourcing pharmaceutical packaging, manufacturing equipment, or contract manufacturing services from Massachusetts-based biotech suppliers. The 20% stock price decline ($5.91 to $4.76) indicates investor concerns about company viability, which may trigger supplier payment delays or contract cancellations. Sellers in pharmaceutical logistics, cold chain management, and manufacturing supplies should diversify supplier relationships and monitor biotech company financial health. Consider shifting 10-15% of sourcing to alternative suppliers to mitigate concentration risk.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"How does the FDA's stricter approval standard affect sellers of clinical trial support products?","The FDA's requirement for well-controlled trials instead of single-arm studies extends pharmaceutical development timelines by 2-4 years, directly increasing demand for clinical trial management software, patient monitoring devices, and regulatory documentation tools. Sellers offering these products should expect 15-25% higher order volumes from biotech companies preparing more comprehensive trial designs. Companies like Replimune now face multi-year confirmatory trials, creating sustained procurement needs for trial infrastructure, data management systems, and quality assurance products. Sellers should position compliance-focused solutions as essential to meeting new FDA standards.",{"title":63,"answer":64,"author":5,"avatar":5,"time":5},"What regulatory compliance investments should sellers prioritize given stricter FDA standards?","The FDA's emphasis on robust clinical data and well-controlled trials creates demand for regulatory consulting services, quality management software, and compliance documentation tools. Sellers should invest in products that help pharmaceutical manufacturers meet enhanced data requirements: electronic data capture systems, statistical analysis software, and regulatory tracking platforms. Companies offering these solutions can expect 20-30% revenue growth from biotech clients preparing for stricter FDA reviews. Prioritize certifications (ISO 13485, 21 CFR Part 11) and partnerships with regulatory consulting firms to establish credibility in this expanding market.",{"title":66,"answer":67,"author":5,"avatar":5,"time":5},"How does Iovance's market consolidation benefit sellers of complementary health products?","With Replimune eliminated as a competitor, Iovance Biotherapeutics' Amtagvi (approved 2024) gains market share in advanced melanoma treatment. This consolidation increases demand for complementary products: patient support services, treatment-related wellness items, skin care products for immunotherapy patients, and monitoring devices. Sellers should develop product lines supporting Opdivo combination therapy patients, as this becomes the dominant treatment pathway. Historical data shows approved cancer treatments generate 30-40% higher demand for supportive care products within 12-18 months of market consolidation. Target oncology patient communities through healthcare provider partnerships.",[69,74,79,84,89,93,97,101,105,109,113,117,121,125,129,132,136,139,143,148,152,157,160,164,168,172,175,179,184,188,192,196,200,205,209,213,217,221,224,228,231,235,239,243,247,251,255,258,262,266,270,274,279,283,287,290,294,298,302,305],{"id":70,"title":71,"source":72,"logo":14,"time":73},731329,"Replimune’s drug for advanced skin cancer fails to win FDA nod again","https://wkzo.com/2026/04/10/replimunes-drug-for-advanced-skin-cancer-fails-to-win-fda-nod-again/","18H AGO",{"id":75,"title":76,"source":77,"logo":5,"time":78},731330,"Replimune (REPL) Faces Setback from FDA on RP1 Approval for Mela","https://www.gurufocus.com/news/8788065/replimune-repl-faces-setback-from-fda-on-rp1-approval-for-melanoma-treatment?mobile=true","21H AGO",{"id":80,"title":81,"source":82,"logo":17,"time":83},731331,"The U.S. Food and Drug Administration (FDA) stated in a complete response letter regarding Replimune Group Inc. that the current clinical data is insufficient to demonstrate significant efficacy of its oncolytic virus therapy, vusolimogene oderparepvec.","https://www.bitget.com/news/detail/12560605356531","2D AGO",{"id":85,"title":86,"source":87,"logo":11,"time":88},731332,"FDA again spurns Replimune melanoma drug","https://finance.yahoo.com/sectors/healthcare/articles/fda-again-spurns-replimune-melanoma-121300685.html","1D AGO",{"id":90,"title":91,"source":92,"logo":38,"time":88},731333,"Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time","https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-replimune-cutting-jobs-as-fda-rejects-rp1-a-second-time-R7NN6KDVMVB65EL2YQQVSNVLJA/",{"id":94,"title":95,"source":96,"logo":24,"time":88},731334,"Replimune’s Skin Cancer Drug Receives Second FDA Rejection","https://www.bloomberg.com/news/articles/2026-04-10/replimune-s-skin-cancer-drug-receives-second-fda-rejection",{"id":98,"title":99,"source":100,"logo":5,"time":88},731335,"Replimune receives FDA rejection for melanoma treatment","https://www.investing.com/news/company-news/replimune-receives-fda-rejection-for-melanoma-treatment-93CH-4608687",{"id":102,"title":103,"source":104,"logo":5,"time":88},731336,"Replimune's (REPL) CRL Revives Regulatory Concerns","https://www.gurufocus.com/news/8788066/replimunes-repl-crl-revives-regulatory-concerns",{"id":106,"title":107,"source":108,"logo":5,"time":88},731337,"Replimune receives FDA rejection for melanoma treatment By Investing.com","https://in.investing.com/news/company-news/replimune-receives-fda-rejection-for-melanoma-treatment-93CH-5333092",{"id":110,"title":111,"source":112,"logo":26,"time":88},731338,"Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma","https://www.manilatimes.net/2026/04/11/tmt-newswire/globenewswire/replimune-receives-complete-response-letter-from-the-fda-for-rp1-biologics-license-application-for-the-treatment-of-advanced-melanoma/2318307",{"id":114,"title":115,"source":116,"logo":19,"time":88},731339,"Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients","https://www.tradingview.com/news/reuters.com,2026:newsml_FWN40T0T1:0-replimune-group-disagrees-with-fda-about-whether-rp1-bla-data-set-is-enough-to-allow-the-medicine-to-be-made-available-to-advanced-cancer-patients/",{"id":118,"title":119,"source":120,"logo":5,"time":88},731340,"Cantor Fitzgerald downgrades Replimune stock rating after second FDA rejection","https://in.investing.com/news/stock-market-news/cantor-fitzgerald-downgrades-replimune-stock-rating-after-second-fda-rejection-93CH-5333067",{"id":122,"title":123,"source":124,"logo":5,"time":88},731341,"FDA setback for Replimune melanoma drug forces job cuts","https://www.stocktitan.net/news/REPL/replimune-receives-complete-response-letter-from-the-fda-for-rp1-qqnp5iiavj1e.html",{"id":126,"title":127,"source":128,"logo":34,"time":88},731342,"Replimune cries foul after FDA rejects melanoma treatment, again","https://firstwordpharma.com/story/7177454",{"id":130,"title":71,"source":131,"logo":14,"time":73},733521,"https://kfgo.com/2026/04/10/replimunes-drug-for-advanced-skin-cancer-fails-to-win-fda-nod-again/",{"id":133,"title":134,"source":135,"logo":27,"time":88},731343,"Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second Time","https://www.barrons.com/articles/replimune-stock-tumbles-after-fda-rejects-skin-cancer-therapy-9cb23536",{"id":137,"title":71,"source":138,"logo":14,"time":73},733520,"https://wtvbam.com/2026/04/10/replimunes-drug-for-advanced-skin-cancer-fails-to-win-fda-nod-again/",{"id":140,"title":141,"source":142,"logo":35,"time":88},731344,"Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)","https://seekingalpha.com/article/4889906-replimune-second-crl-may-have-sealed-rp1-fate-its-hard-to-see-positives",{"id":144,"title":145,"source":146,"logo":40,"time":147},733523,"FDA Review Looms As Replimune Faces Weak Technical Setup","https://www.aol.com/articles/fda-review-looms-replimune-faces-183107002.html","6H AGO",{"id":149,"title":150,"source":151,"logo":28,"time":88},731345,"FDA Issues Second CRL for RP1/Nivolumab in Advanced Melanoma","https://www.targetedonc.com/view/fda-issues-second-crl-for-rp1-nivolumab-in-advanced-melanoma",{"id":153,"title":154,"source":155,"logo":39,"time":156},731422,"Replimune Shares Sink After FDA Rejects Skin-Cancer Drug a Second Time","https://www.wsj.com/livecoverage/cpi-inflation-data-stock-market-04-10-2026/card/replimune-shares-sink-after-fda-rejects-skin-cancer-drug-a-second-time-wyMCCX7ahV0wSKsLh4Ea","23H AGO",{"id":158,"title":71,"source":159,"logo":14,"time":73},733522,"https://whtc.com/2026/04/10/replimunes-drug-for-advanced-skin-cancer-fails-to-win-fda-nod-again/",{"id":161,"title":162,"source":163,"logo":30,"time":88},731346,"REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?","https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto",{"id":165,"title":166,"source":167,"logo":32,"time":88},731423,"Replimune's drug for advanced skin cancer fails to win FDA nod again","https://www.reuters.com/legal/litigation/us-fda-declines-approve-replimunes-drug-advanced-skin-cancer-2026-04-10/",{"id":169,"title":145,"source":170,"logo":15,"time":171},733525,"https://finance.yahoo.com/sectors/healthcare/articles/fda-review-looms-replimune-faces-163107317.html","9H AGO",{"id":173,"title":111,"source":174,"logo":5,"time":88},731347,"https://www.bitget.com/news/detail/12560605357324",{"id":176,"title":177,"source":178,"logo":37,"time":88},731424,"FDA rejects Replimune’s melanoma prospect for second time","https://www.fiercebiotech.com/biotech/fda-refuses-replimunes-melanoma-prospect-second-time",{"id":180,"title":181,"source":182,"logo":31,"time":183},733524,"USFDA Rejects Replimune's RP1 for Advanced Melanoma, Flags Insufficient Data","https://medicaldialogues.in/news/industry/pharma/usfda-rejects-replimunes-rp1-for-advanced-melanoma-flags-insufficient-data-168460","7H AGO",{"id":185,"title":186,"source":187,"logo":5,"time":88},731348,"Replimune (REPL) Stock Plunges Nearly 20% Following Second FDA Rejection of Melanoma Treatment","https://parameter.io/replimune-repl-stock-plunges-nearly-20-following-second-fda-rejection-of-melanoma-treatment/",{"id":189,"title":190,"source":191,"logo":36,"time":88},731425,"Replimune skin cancer drug that became FDA flashpoint is rejected again","https://www.statnews.com/2026/04/10/skin-cancer-replimune-fda-approval/",{"id":193,"title":194,"source":195,"logo":13,"time":88},733527,"Second CRL for Replimune’s RP-1 for melanoma","https://www.bioworld.com/articles/730363-second-crl-for-replimunes-rp-1-for-melanoma",{"id":197,"title":198,"source":199,"logo":22,"time":88},731349,"Why Is Replimmune Stock Sinking Friday? - Replimune Group (NASDAQ:REPL)","https://www.benzinga.com/news/fda/26/04/51761286/fda-again-rejects-replimune-cancer-therapy-says-evidence-falls-short",{"id":201,"title":202,"source":203,"logo":5,"time":204},733526,"Replimune (REPL) Faces Major Setback After FDA Rejects RP1 Appro","https://www.gurufocus.com/news/8788685/replimune-repl-faces-major-setback-after-fda-rejects-rp1-approval","11H AGO",{"id":206,"title":207,"source":208,"logo":23,"time":88},731350,"FDA Rejects Replimune’s Skin Cancer Drug Again in Flashpoint Decision","https://www.el-balad.com/16908337",{"id":210,"title":211,"source":212,"logo":5,"time":88},731351,"Replimune (REPL) Stock Falls 19% After FDA Rejects RP1 Melanoma Drug Application Again","https://coincentral.com/replimune-repl-stock-falls-19-after-fda-rejects-rp1-melanoma-drug-application-again/",{"id":214,"title":215,"source":216,"logo":25,"time":88},731352,"Replimune’s advanced melanoma drug rebuffed by FDA for second time","https://www.biospace.com/fda/replimunes-advanced-melanoma-drug-rebuffed-by-fda-for-second-time",{"id":218,"title":219,"source":220,"logo":5,"time":88},731353,"REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug","https://www.msn.com/en-us/health/other/repl-stock-on-track-for-worst-drop-in-nearly-7-months-ahead-of-fda-decision-on-skin-cancer-drug/ar-AA20rQj5",{"id":222,"title":86,"source":223,"logo":12,"time":88},731354,"https://www.biopharmadive.com/news/replimune-fda-reject-melanoma-rp1/816659/",{"id":225,"title":226,"source":227,"logo":18,"time":88},731355,"Fda says data insufficient to conclude effectiveness of Replimune's vusolimogene oderparepvec","https://www.marketscreener.com/news/fda-says-data-insufficient-to-conclude-effectiveness-of-replimune-s-vusolimogene-oderparepvec-ce7e50d9db89f524",{"id":229,"title":150,"source":230,"logo":29,"time":88},731356,"https://www.cancernetwork.com/view/fda-issues-second-crl-for-rp1-nivolumab-in-advanced-melanoma",{"id":232,"title":233,"source":234,"logo":21,"time":88},731357,"FDA rejects Replimune cancer therapy, saying company didn’t resolve trial doubts","https://endpoints.news/fda-rejects-replimune-cancer-therapy-saying-company-didnt-resolve-trial-doubts/",{"id":236,"title":237,"source":238,"logo":33,"time":88},731358,"FDA Issues CRL for RP1 Plus Nivolumab in Advanced Melanoma","https://www.onclive.com/view/fda-issues-crl-for-rp1-plus-nivolumab-in-advanced-melanoma",{"id":240,"title":241,"source":242,"logo":5,"time":88},731359,"Replimune (REPL) Shares Decline Following FDA Letter","https://www.gurufocus.com/news/8787524/replimune-repl-shares-decline-following-fda-letter?mobile=true",{"id":244,"title":103,"source":245,"logo":5,"time":246},734393,"https://www.gurufocus.com/news/8788066/replimunes-repl-crl-revives-regulatory-concerns?mobile=true","16H AGO",{"id":248,"title":249,"source":250,"logo":5,"time":246},732292,"REPL stock crashes 19% after FDA refuses RP1 drug | Tap to know more | Inshorts","https://inshorts.com/en/news/repl-stock-crashes-19--after-fda-refuses-rp1-drug-1775841133091",{"id":252,"title":253,"source":254,"logo":41,"time":88},732293,"Replimune Group, Inc. Receives Complete Response Letter from FDA for RP1 BLA in Advanced Melanoma Treatment","https://www.quiverquant.com/news/Replimune+Group%2C+Inc.+Receives+Complete+Response+Letter+from+FDA+for+RP1+BLA+in+Advanced+Melanoma+Treatment",{"id":256,"title":71,"source":257,"logo":14,"time":73},734395,"https://wsau.com/2026/04/10/replimunes-drug-for-advanced-skin-cancer-fails-to-win-fda-nod-again/",{"id":259,"title":260,"source":261,"logo":5,"time":88},732294,"Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummet","https://www.bitget.com/news/detail/12560605357455",{"id":263,"title":107,"source":264,"logo":5,"time":265},734394,"https://au.investing.com/news/company-news/replimune-receives-fda-rejection-for-melanoma-treatment-93CH-4357353","5H AGO",{"id":267,"title":268,"source":269,"logo":5,"time":88},731360,"Replimune (REPL) Faces Regulatory Setback on Melanoma Treatment","https://www.gurufocus.com/news/8787523/replimune-repl-faces-regulatory-setback-on-melanoma-treatment",{"id":271,"title":272,"source":273,"logo":5,"time":88},732295,"Replimune (REPL) Stock Plunges 19% Following Second FDA Rejection of Melanoma Treatment","https://blockonomi.com/replimune-repl-stock-plunges-19-following-second-fda-rejection-of-melanoma-treatment/",{"id":275,"title":276,"source":277,"logo":5,"time":278},734397,"Replimune (REPL) Faces Major Setback After FDA Rejects RP1 Approval","https://www.gurufocus.com/news/8788685/replimune-repl-faces-major-setback-after-fda-rejects-rp1-approval?mobile=true","8H AGO",{"id":280,"title":281,"source":282,"logo":10,"time":88},731361,"Replimune issued Complete Response Letter for RP1 for advanced melanoma","https://www.tipranks.com/news/the-fly/replimune-issued-complete-response-letter-for-rp1-for-advanced-melanoma-thefly-news",{"id":284,"title":285,"source":286,"logo":5,"time":88},732296,"Replimune (REPL) Shares Plunge 19% as FDA Issues Second Rejection for Melanoma Treatment","https://blockonomi.com/replimune-repl-shares-plunge-19-as-fda-issues-second-rejection-for-melanoma-treatment/",{"id":288,"title":71,"source":289,"logo":14,"time":73},734396,"https://kelo.com/2026/04/10/replimunes-drug-for-advanced-skin-cancer-fails-to-win-fda-nod-again/",{"id":291,"title":292,"source":293,"logo":16,"time":88},731362,"Replimune lead drug rejected by FDA again (REPL:NASDAQ)","https://seekingalpha.com/news/4574103-replimune-lead-drug-rejected-fda-again",{"id":295,"title":296,"source":297,"logo":5,"time":88},732297,"Replimune (REPL) Shares Plunge 19% Following Second FDA Rejection of RP1 Melanoma Treatment","https://blockonomi.com/replimune-repl-shares-plunge-19-following-second-fda-rejection-of-rp1-melanoma-treatment/",{"id":299,"title":300,"source":301,"logo":20,"time":88},731363,"US FDA declines to approve Replimune's drug for advanced skin cancer","https://www.yahoo.com/news/articles/us-fda-declines-approve-replimunes-152426858.html",{"id":303,"title":268,"source":304,"logo":5,"time":88},732298,"https://www.gurufocus.com/news/8787523/replimune-repl-faces-regulatory-setback-on-melanoma-treatment?mobile=true",{"id":306,"title":307,"source":308,"logo":5,"time":88},731364,"REPL vs IOVA in focus ahead of key FDA decision on RP1 | Tap to know more | Inshorts","https://inshorts.com/en/news/repl-vs-iova-in-focus-ahead-of-key-fda-decision-on-rp1-1775815515614","#4ea578ff","#4ea5784d",1775971868990]